INIS
cancer
100%
patients
100%
breasts
96%
therapy
51%
carcinomas
46%
metastases
36%
receptors
30%
chemotherapy
22%
surgery
21%
humans
15%
hormones
15%
growth factors
15%
weight
15%
cost
15%
drugs
15%
comparative evaluations
14%
hazards
11%
usa
11%
european union
11%
concentration
11%
range
7%
populations
7%
geometry
7%
pathology
5%
Keyphrases
Breast Cancer Patients
46%
Ductal Carcinoma in Situ
46%
Neoadjuvant Systemic Therapy
32%
Advanced Breast Cancer
30%
Invasive Breast Cancer
30%
Subnational Analysis
30%
Human Epidermal Growth Factor Receptor 2 (HER2)
23%
In Situ Component
21%
HER2-positive
17%
HER2 Metastatic Breast Cancer
17%
Cyclin-dependent Kinase 4 (CDK4)
17%
Pathological Complete Response
17%
Overall Survival
17%
Metastatic Breast Cancer
16%
Time Trends
15%
Treatment Characteristics
15%
Hormone Receptor-positive
15%
World Time
15%
Survival Characteristics
15%
Visceral Crisis
15%
Trastuzumab
15%
Patient Characteristics
15%
Trastuzumab Resistance
15%
Survival Treatment
15%
Surgical Prognosis
15%
Sacituzumab Govitecan
15%
HER2+
15%
Breast Reconstruction
15%
Dosing Regimen
15%
Cost Savings
15%
Medicine and Dentistry
Breast Cancer
46%
Intraductal Carcinoma
46%
Systemic Therapy
34%
Metastatic Breast Cancer
30%
Overall Survival
18%
CDK4/6 Inhibitor
17%
Observational Study
15%
Patient Characteristics
15%
Hormone Receptor
15%
Quadrantectomy
15%
Neoadjuvant Chemotherapy
15%
Triple Negative Breast Cancer
15%
Hormone Therapy
6%
Cancer Diagnosis
5%